Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% ...

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The stock's fall snapped a two-day winning streak.

HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...

H.C. Wainwright lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $50 from $75 and keeps a Buy rating on the shares. The firm ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...